Showing 601 - 620 results of 122,865 for search '(( 5 ((a decrease) OR (nn decrease)) ) OR ( a ((non decrease) OR (point decrease)) ))', query time: 1.66s Refine Results
  1. 601
  2. 602
  3. 603
  4. 604
  5. 605
  6. 606
  7. 607

    Intracameral injections of ATX inhibitor decreases IOP in rabbits. by Padma Iyer (141117)

    Published 2012
    “…Drug treated eyes showed a significant decrease in IOP from the baseline (by 6–7 mm Hg) at 24 and 48 hrs based on paired t-test. …”
  8. 608
  9. 609
  10. 610
  11. 611
  12. 612

    Nur77 knockdown decreases cell viability and proliferation. by Alexa Tenga (2161780)

    Published 2016
    “…<p>(A) Daoy cells were transfected with 20 nM siNur77 or non-targeting control (NT), and cell viability was measured via the CellTiter-Glo assay every day for 3 days. …”
  13. 613

    Human preterm infants diagnosed with IUGR have decreased Paneth cell counts compared to preterm non-IUGR control infants. by Camille M. Fung (844334)

    Published 2016
    “…(A) IUGR infants had similar numbers of goblet cells per 100 epithelial cells compared to non-IUGR infants (p = 0.5). …”
  14. 614

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  15. 615
  16. 616
  17. 617
  18. 618
  19. 619

    Deterioration of the anammox process at decreasing temperatures and long SRTs by Maaike Hoekstra (3915545)

    Published 2017
    “…The long SRT leads to an increase of non-active and non-anammox cells in the reactor, thereby decreasing the biomass-specific activity.…”
  20. 620

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”